### 2022 American Academy of Optometry Mid-Year Press Conference

**Thursday, May 12, 8:00 to 9:00 pm ET**

<table>
<thead>
<tr>
<th>Company</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Academy of Optometry</td>
<td>Welcome</td>
<td>Timothy T. McMahon, OD, FAAO AAO President</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Edward Chu, OD, FAAO Press Conference Chair</td>
</tr>
<tr>
<td>Lenz Therapeutics</td>
<td>Aceclidine for the Treatment of Presbyopia</td>
<td>Eef Schimmelpennink CEO</td>
</tr>
<tr>
<td>Tarsus Pharmaceuticals</td>
<td>Demodex Blepharitis: TP-03 and Saturn-2 Pivotal Trial</td>
<td>Bobby Azamian, MD, PhD President &amp; Chief Executive Officer</td>
</tr>
<tr>
<td>Allergan, an AbbVie Company</td>
<td>Vuity™</td>
<td>Dave LeCause General Manager</td>
</tr>
<tr>
<td>Avellino Labs</td>
<td>AvaGen: The Genetic Eye Test</td>
<td>Joe Boyd Global Head, Sales &amp; Marketing</td>
</tr>
<tr>
<td>Heru, Inc.</td>
<td>The Heru™ Platform</td>
<td>Mohamed Abou Shousha, MD, PhD Founder &amp; CEO</td>
</tr>
<tr>
<td>RevitalVision</td>
<td>RevitalVision</td>
<td>Yair Yahav CEO</td>
</tr>
<tr>
<td>NovaSight Ltd.</td>
<td>CureSight™</td>
<td>Ran Yam CEO</td>
</tr>
<tr>
<td>Eschenbach Optik of America, Inc.</td>
<td>Vario Digital 22 FHD</td>
<td>Timothy Gels Director of Marketing</td>
</tr>
<tr>
<td>Innova Systems, Inc.</td>
<td>Rabin Cone Contrast Testing</td>
<td>Pinakin Davey, OD, PhD, FAAO Tenured Professor, Western University of Health Sciences</td>
</tr>
<tr>
<td>M&amp;S Technologies, Inc.</td>
<td>Smart System® VR Headset</td>
<td>Mike Umali National Sales Manager</td>
</tr>
</tbody>
</table>

Thank you to all presenters; the AAO Staff, including Kayla Ritten and David Harrison; the AAO Communications Committee (Tammy Than, Richard Trevino, Arti Shah, Reena Patel, and Gene Wong); our Press Conference Chair, Edward Chu, OD, FAAO (Edward.Chu@va.gov) and most of all, to all of you in attendance this evening.

Save the date for the Academy’s Annual Meeting Press Conference, Tuesday, October 25 featuring both industry presentations and scientific paper and poster presentation highlights from Academy 2022 San Diego.
MEDIA RELEASE

Avellino Celebrates Anniversary Launch of AvaGen™ this June and Further Empowering Eye Care Professionals to Help Detect Keratoconus

MENLO PARK, Calif. – (May 10, 2022) – Avellino Lab USA, Inc. (Avellino) is celebrating the first anniversary of the launch of AvaGen™, The Genetic Eye Test, which was available nationwide on June 2, 2021.

The only genetic test of its kind on the US market, AvaGen helps detect a patient’s risk of keratoconus and the presence of other corneal dystrophies. For keratoconus, a polygenic risk score (PRS) is provided by analyzing 75 keratoconus-related genes and more than 2,000 variants of those genes to develop an actionable genetic risk score.

For corneal dystrophies, the test detects the presence of 70 TGFBI gene variants and provides a conclusive diagnosis of corneal dystrophy sub-types, including Epithelial Basement Membrane, Granular and Lattice disease distinctions, Reis-Bucklers, Schnyder's-like and Theil-Behnke.

During a presentation at the 2022 American Academy of Optometry Mid-Year Press Conference, Avellino Global Head of Sales and Marketing Joe Boyd provided an overview of AvaGen and a case study that illustrates how the test can help guide management and treatment for patients.

The case study spotlights how AvaGen can test family members of keratoconus patients and help with early management and intervention. As Mr. Boyd shared during the conference, the case study patient had been diagnosed with unilateral keratoconus and underwent corneal cross-linking in the right eye. This patient is a mother to an 8-year-old son, and she agreed to have him tested with AvaGen to understand the genetic risk of keratoconus. The son demonstrated a moderate genetic risk score, which helped inform the doctor to increase the frequency of patient monitoring.

AvaGen requires only a simple cheek swab that is sent to Avellino’s high complexity CLIA-certified lab for analysis. An eye care professional receives results via an intuitive report via a HIPAA-secured portal. Genetic counseling is also provided to ensure eye care professionals and their patients understand the result and possible impact on patient management. The test is designed to be used by trained eye care professionals and in conjunction with other diagnostic instrumentation, such as refractive error analysis, slit lamp examination, keratometry, topography and tomography.

About Avellino
Avellino Lab USA, Inc. is a global leader in genetic molecular diagnostics at the forefront of precision medicine for eye care. With a long-term mission to develop personalized approaches to improve health and disease management through genomics, the company is developing a transformative genetic diagnostics product pipeline, as well as genetic therapeutics leveraging CRISPR gene editing, to better manage, and potentially cure, inherited diseases. The company also developed the Avellino SARS-CoV-2 RT-PCR diagnostic test (AvellinoCoV2) to aid in COVID-19 pandemic testing efforts in the US and was the first private, independent company in the US to receive an EUA for its COVID-19 test. Avellino is headquartered in Menlo Park, California, with operations in Korea, Japan, and UK, with future plans for further expansion in both Asia and Europe. To learn more about Avellino, visit www.avellino.com.

# # #

Media Contact
Angela Lapré
Global Head of Corporate Communications
Angela.Lapre@avellino.com
650-788-0374
Company Overview

Leadership:

- Founder and Chairman of the Board
  Gene Lee
- President and CEO
  Jon Robson
- Chief Strategy Officer and Corporate Secretary
  Thomas Kim
- Chief Scientific Officer
  Nazneen Aziz, Ph.D.
- Chief Financial Officer and Treasurer
  Cyril Allouche
- Chief Technology Officer
  Laiq Ahmad
- Global Head of Sales and Marketing
  Joe Boyd
- Global Head of Health Policy
  Genya Dana, Ph.D.
- Global Head of Business and Corporate Development
  Eric Bernabei
- Global Head of Operations
  John Hong
- Global Head of Human Resources
  Shveta Bidani
- Global Head of Corporate Communications
  Angela Lapré

Year and Country Founded: 2008, South Korea
Number of Employees (Global): 255
URL: www.Avellino.com

Products – Cornea

- AvaGen™ - Quantifies the genetic risk of keratoconus and the presence of TGFBI related corneal dystrophies (Available in the US)
- Universal Test – Genetic diagnostic assay to detect the presence of TGFBI corneal dystrophy (Available in Korea and Japan)

Products – Infectious Disease

- AvellinoCoV2 Test – Swab-based test used to detect the SARS-CoV-2 virus
- AvellinoCoV2 Respiratory Panel – Swab-based test used to detect the SARS-CoV-2 virus, influenza A, influenza B, and Respiratory Syncytial Virus (RSV)

Number of Patents: 31 registered; 66 filed
Number of Laboratories (Global): 9

About Avellino

Avellino Lab USA, Inc. is a global leader in genetic molecular diagnostics at the forefront of precision medicine for eye care. With a long-term mission to develop personalized approaches to improve health and disease management through genomics, the company is developing a transformative genetic diagnostics product pipeline, as well as genetic therapeutics leveraging CRISPR gene editing, to better manage, and potentially cure, inherited diseases. The company also developed the Avellino SARS-CoV-2 RT-PCR diagnostic test (AvellinoCoV2) to aid in COVID-19 pandemic testing efforts in the US and was the first private, independent company in the US to receive an EUA for its COVID-19 test. Avellino is headquartered in Menlo Park, California, with operations in Korea, Japan, and UK with future plans for further expansion in both Asia and Europe.

Media Contact

Angela Lapré | Angela.Lapre@Avellino.com | 650.788.0374
Assessing keratoconus is multifactorial. Until now, genetic data has been missing from the equation.

**AvaGen™ is:**

**PERSONALIZED**
A fast and easy cheek swab sample is used to measure and assess keratoconus risk, and report the presence of TGFBI corneal dystrophies.

**PRECISE**
Objective, quantitative genetic data reliably guides confident management and treatment decisions.

**PROACTIVE**
Enables early, proactive assessment and actions not possible using reactive historical methods used after onset of symptoms.

CONFIDENTLY EMPOWERS EYE CARE PROFESSIONALS WITH PERSONALIZED PATIENT GENETIC DATA TO PROTECT AND PRESERVE VISION.
EMPOWERING A HIGHER LEVEL OF PERSONALIZED TARGETED EYE CARE

With Next-Generation Sequencing AvaGen™ analyzes:

75 Keratoconus Related Genes
2k+ Keratoconus Related Gene Variants
1 TGFBI Gene
70 TGFBI Gene Variants

AVELLINO ALGORITHM

KERATOCONUS RISK
CORNEAL DYSTROPHY PRESENCE

WHEN TO USE AVAGEN™

AvaGen™ may be used for early diagnosis and management of keratoconus, corneal crosslinking decisions, and for refractive surgery decisions.

1 Family History: Test family members of keratoconus patients helps with early intervention.

2 Irregular Topography: Concerns in the cornea such as topography, against-the-rule or oblique astigmatism in younger patients, or thin pachymetry.

3 Refractive Concerns: Unstable refractions such as progressive myopia or astigmatism, or steep corneal curvature.

4 Corneal Refractive Surgery Decisions: Test suspicious pre-refractive surgery patients, post-LASIK ectasia patients, young laser vision correction candidates, corneal dystrophy patients, or for decisions between LASIK vs. PRK.

For more information on AvaGen™, The Genetic Eye Test, please visit: Avellina.com/avagen

Know early. Act personally. Decide confidently.
MIAMI – May 3, 2022 – Vision diagnostics leader, Heru Inc., is pleased to be a part of the American Academy of Optometry 2022 mid-year virtual press conference where Chief Executive Officer, Mohamed Abou Shousha, MD, FRCS, PhD, will be presenting on Heru’s suite of comprehensive vision diagnostic exams. This includes their latest release, the Fast Pattern Suprathreshold Visual Field, which performs rapid visual field screening without refractive correction.

Born out of the University of Miami’s Bascom Palmer Eye Institute, Heru’s award-winning diagnostic platform is the first of its kind. Its solution enables physicians to perform six vision diagnostic exams, supported with five revenue generating CPT codes, in a single, space-saving, wearable AR/VR platform.

“Heru recently reached a significant clinical milestone over 20,000 patient eyes screened which enforces our commitment to provide affordable, reliable and accessible vision care,” said Dr. Mohamed Abou Shousha. “We have an ambitious pipeline and are committed to delivering best-in-class wearable technology to physicians. Technology that will empower them to effectively diagnose, treat and manage vision disorders to improve their patient’s quality of life.”

Heru’s new Fast Pattern empowers physicians to perform fast and efficient screening without trial lenses, with real-time clinical results, which may facilitate early detection and intervention in progressive eye conditions such as glaucoma, age-related macular degeneration (AMD), and cataracts. In addition to the Fast Pattern Suprathreshold visual field, testing modalities available on the platform include Full Threshold visual fields, Contrast Sensitivity, Color Vision, both Ishihara and Farnsworth D-15, and Dark Adaptation.

Stop by Heru’s booth for a demo and learn more about the company’s latest advancements at this year’s American Academy of Optometry Meeting in San Diego. For more information about Heru’s wearable diagnostic platform, visit www.seeheru.com.
About Heru

Heru Inc. (www.seeheru.com) is a medical software company focused on the development of next-generation diagnostic solutions leveraging commercially available AR/VR head-mounted displays. The company pioneered the first multi-modal wearable solution, which has revolutionized healthcare by introducing several diagnostic modalities in a single platform. Heru is leveraging its award-winning platform to build a comprehensive diagnostic solution that is strongly correlated to the current standard of care and exceeds traditional standards of care in usability, cost, size, and portability. Future development includes therapeutic applications for personalized augmented vision correction.

In May 2021, Heru announced a $30 million Series A funding round, led by global investment firm D1 Capital Partners with participation from SoftBank’s SB Opportunity Fund and existing investors.

Heru was born out of the University of Miami’s Bascom Palmer Eye Institute. In December 2020, Heru announced a seed round led by Fred Drasner, Maurice R. Ferré, MD, Frederic H. Moll, MD, and a consortium of investors with extensive experience developing, launching, and scaling cutting-edge medical technologies.

Media Inquiries:
Brandon Barber
media@heru.net
New Powerful Tool for Optometrists to Improve Vision Beyond Optical Correction.

Software Clinically Proven to Treat Adult Amblyopia (Lazy Eye), Eye Diseases and Vision Impairments.

*Prescribed software with new approved CPT Codes is now available for optometrists to treat millions in the U.S. suffering from impaired vision.*

MODI’IN, Israel – April 26, 2022 – RevitalVision announced that its standalone therapeutic vision training software, the only FDA-approved product for market, and clinically proven to improve vision in adult amblyopia (age nine-plus), is now available to use by eyecare professionals globally.

The software, which received a unique CPT reimbursement code from the American Medical Association (AMA) for the treatment of amblyopia, is effective in improving vision in multiple vision impairments and eye diseases, such as congenital nystagmus, stargardt diseases, post LASIK, after cataract surgery and more.

“The program enhances vision by probing specific neuronal interactions, using a set of patients- specific stimuli that induce improvement of contrast sensitivity functions, which results in improved visual acuity and also stereo acuity in amblyopia. We are working to continue developing our clinical evidence portfolio and will work to make RevitalVision the new standard of care for treating adult amblyopia and other vision impairments.” said Yair Yahav, chief executive officer, RevitalVision.

“RevitalVision is a great advance for adults and older children with amblyopia and nystagmus who we previously could not treat,” said Yair Morad, MD, Professor in Ophthalmology at Tel Aviv University, the Head of the Pediatric Ophthalmology Unit at Shamir Medical Center in Israel, and co-chair of the Scientific Bureau of the WSPOS, who is an advisor to RevitalVision.

RevitalVision neural training program improves vision by 2.5 lines on average on the visual acuity chart, and 100% in contrast sensitivity, beyond the critical age and beyond occlusion therapy. Most amblyopic patients also improve stereo acuity and binocular functions.

RevitalVision user friendly and easy to use web app vision training technology platform is performed from the comfort of the patient’s home computer for three to four 30-minute home training sessions per week, for a period of three months. Through repetitive practice of defined visual tasks, the brain is trained to be more efficient in processing visual information. RevitalVision specialized algorithms analyze performance and continuously adjust training sessions to improve vision, customized to patients’ specific needs.

A clinician is able to closely monitor patient progress through an in-person office visit to measure actual vision improvement after 20 and 40 sessions, by remote
monitoring of patient’s training activity by actively accessing the management portal, and by receiving automated reports from the system.

RevitalVision uses an **Open Access Strategy**! Any eyecare specialist can self-register on the company’s website and have immediate access to use the system without any upfront costs.

# # #

**About RevitalVision**
RevitalVision, developers of a unique therapeutic vision training software that improves vision in patients suffering from different eye diseases & visual impairments, when no other alternative treatment is available or effective. RevitalVision’s breakthrough technology is the only clinically proven and FDA approved therapy with efficacy claim for improving vision in adult amblyopia, affecting three percent of the U.S. population.

For additional company information, please visit [https://www.revitalvision.com](https://www.revitalvision.com)

**Media Relations Contact:**
Rona Erlich
Marketing Director, RevitalVision
+1 785 856 0417
+972 52 6066 734
rona@revitalvision.com
NovaSight is pioneering pediatric vision care in the digital age

NovaSight, an Israeli pediatric eyecare company, focuses on bringing pediatric vision care into the digital age. The company was founded in 2016 and has experienced rapid growth by delivering complete end-to-end eye-tracking based solutions for accurate assessment and treatment of early vision disorders.

NovaSight’s flagship product, the CureSight® system, is an eye-tracking based treatment for amblyopia designed to replace traditional eye patching. CureSight is a digital device that trains the visual system to use both eyes simultaneously, while the user watches unlimited streamed video content from various media platforms available on the device (through red-blue treatment glasses). By using sophisticated algorithms and eye-tracking technology, the system blurs the center of vision of the image that is shown to the dominant eye using real-time image processing. This encourages the brain to complete the fine details perceived by the amblyopic eye and trains the two eyes to work as a team. The device is designed to be used at home, and it shares treatment reports with caregivers via a cloud portal.

Earlier this year, the company announced positive pivotal data from its multicenter, randomized, controlled trial. The study, which randomized 103 participants aged 4 to 9, compared the improvement in visual outcomes achieved by CureSight digital treatment versus eye patching - the current gold-standard-of-care treatment. This is the first ever pivotal study in which a digital device was shown to be non-inferior to eye patching for amblyopia treatment in children.

In addition to achieving the non-inferiority primary endpoint, the topline analyses from the pivotal study demonstrated that Best Corrected Visual Acuity (BCVA) improvement at week 16 was larger in the treatment group compared to the patching control group. In addition, a significant stereo acuity improvement was observed in both groups. No serious adverse events were observed in either treatment arms (CureSight or patching) and all non-serious adverse events were transient and self-limiting.

The study also evaluated adherence and patient satisfaction. The mean adherence to CureSight use during the study among subjects evaluated at the week 16 visit (N=43) was 93%, as measured by the CureSight’s eye-tracking system. In addition, 95% of parents reported that they are likely or very likely to choose the CureSight digital treatment over patching.
“We are delighted to have completed the CureSight study and further validate its safety and effectiveness as measured by visual acuity and stereoaucity improvement in comparison to patching and with a high safety profile and user satisfaction. Eye patching is effective when patients are compliant; however, patching is often associated with insufficient adherence due to the discomfort it brings to the patient and the social stigma that many children experience when wearing a patch” said NovaSight CEO Ran Yam. “The success of the CureSight study is a critical step toward bringing this treatment for lazy eye to children around the world and to potentially modernizing the standard of care.”

Following on the recently granted CE mark approval for CureSight in Europe, completion of the CureSight pivotal trial represents a significant step forward to securing US FDA clearance. With three unique CPT codes for the CureSight treatment already effective since January 2022, NovaSight is poised to take the next step with submission of its 510(k) application and the expected clearance by the end of the year.

The EyeSwift®PRO, the company’s second flagship product, is an eye tracking-based comprehensive vision assessment device which accurately and objectively screens for multiple vision impairments within seconds and can be used by any trained individual. The system has a powerful portfolio of vision protocols, such as myopia management, amblyopia monitoring, reading, and more. Each protocol performs the relevant tests and outputs a clear report which can be easily understood by the operator, as well as by the patient or parent. It is designed for both pediatric and adult patients and requires minimal patient cooperation – patients simply watch fun short, animated videos while being tested.

The EyeSwift®PRO is the successor of the current generation EyeSwift® device which is distributed globally by EssilorLuxottica. It is currently in a pre-market phase and is expected to be available in the US by mid-2023.

NovaSight will be an exhibitor at the upcoming meeting of the American Academy of Optometry (AAOPT), from October 26 to 29, in San Diego. This will be the first time NovaSight is presenting its technology and products to the optometry industry.
About NovaSight:
NovaSight is an Israeli company that focuses on bringing pediatric vision care into the digital age. Founded in 2016, NovaSight has experienced rapid growth by delivering complete end-to-end eye tracking-based solutions for accurate assessment and treatment of early vision disorders.
NovaSight offers two flagship products, both ideally positioned for digital diagnostics and home treatment: The CureSight™ system is an eye tracking-based treatment for lazy eye designed to replace traditional eye patching. The EyeSwift™ system is a comprehensive vision assessment device which accurately and objectively screens for multiple vision impairments within seconds. Additional pipeline products not yet in distribution include the ActiveGlass®, a wearable solution for myopia (short-sightedness) control, targeted to bring significant advantages over existing solutions in order to combat the myopia global epidemic, and TrackSight™, a software solution that monitors real-time visual health and promotes myopia prevention while using screens.
NovaSight’s management and advisory board is composed of executives, physicians, researchers, and key opinion leaders in the field of vision care.

For more information visit www.nova-sight.com

Find out more about CureSight and EyeSwift™

Contacts:
Jenny Goldman
Marketing Manager
jenny@nova-sight.com

Disclaimers
EyeSwift™ and CureSight™ are investigational devices, limited by federal (or United States) law to investigational use.
Enhance your space.

We do more than opticals.

Grow your company’s brand.

Re-imagine your office flow.

Collaborative Design & Innovation Process

Make a statement with your office

We understand how unique the optometry industry is, and thus the design of your practice must be specific to the day-to-day operations and functions with your office.

Whether you are building new, renovating or adding to your existing practice, we will conceptualize your ideas into a design that features a functional office flow, trendsetting optical displays and distinctive exterior architecture.

35+ years of architectural experience

Our Office
201 Main Street Janesville, Iowa
info@optometricarchitects.com
319-987-2101

Architectural Designs (Interior & Exterior) Complimentary Consultation Interior Space Planning Construction Management